Skip to main content
Premium Trial:

Request an Annual Quote

Sistemic, NHS Scotland Developing Biomarkers for Diabetes-related Sight Loss

NEW YORK (GenomeWeb News) – Sistemic today announced an agreement with NHS Scotland to develop biomarkers for the early detection of diabetic retinopathy and infective keratitis.

Financial and other terms of the deal were not disclosed.

In a statement, Sistemic Chief Scientific Officer Vincent O'Brien said that while the increase in people with diabetes is well documented, "less well appreciated is that retinopathy is the largest cause of blindness in working age people and has a massive impact on quality of life as well as a huge cost burden on the NHS. … The potential to combine the Sistemic technology for understanding changes in miRNA and then using these to guide understanding of what is happening inside the eye is a very exciting prospect."

Headquartered in Glasgow, UK, Sistemic provides miRNA-based services and kit-based products to the pharmaceutical, biotechnology, and cell therapy markets. Among the products it offers are those for miRNA profiling, the analysis of changes to miRNAs "when a cell is perturbed by a stimulus," and the analysis of changes to miRNAs within a "multilayered" biological context, the company said on its website.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.